FibroBiologics, Inc. (FBLG)
- Previous Close
11.68 - Open
11.06 - Bid --
- Ask --
- Day's Range
9.63 - 11.07 - 52 Week Range
6.53 - 46.00 - Volume
100,696 - Avg. Volume
99,336 - Market Cap (intraday)
330.79M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
www.fibrobiologics.comRecent News: FBLG
Compare To: FBLG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FBLG
Valuation Measures
Market Cap
330.79M
Enterprise Value
323.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
264.00
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-20.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-66.75%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-19.06M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
9.16M
Total Debt/Equity (mrq)
150.68%
Levered Free Cash Flow (ttm)
3.83M